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Received May 24, 2010; accepted October 12, 2010AbstractTransitional cell carcinoma (TCC) of the urinary tract is the most frequent malignancy following renal transplantation reported in Taiwan. A
67-year-old female underwent bilateral nephrouretectomy and bladder cuff excision because of bilateral hydronephrosis 5 years after cadaveric
renal transplantation. The pathologic report was only atrophied kidney. Pelvic sonography and abdominal computed tomography showed
a pelvic mass 8 years after transplantation. After gynecological surgery, the pathologic report of the left ovarian tumor was TCC, high grade,
stage IIA. The patient then underwent four cycles of postoperative chemotherapy with carboplatin and gemcitabine. TCC of the ovary is a rare,
recently recognized subtype of ovarian surface epithelial cancer. We present the first case of primary ovarian TCC following renal transplant.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Renal transplant (RTx) recipients have a marked increase in
cancer risk at awidevariety of sites.Malignant tumors developed
in 15e20% of recipients 10 years after RTx.1 In different
geographic areas, the prevalence and characteristics of post-
transplant malignancy show considerable differences. The
predominant malignant tumors after RTx in Western countries
are lymphomas, post-transplant lymphoproliferative disorders
and carcinomas of the skin and lips, followed by cancers
involving the genitourinary system.2 Recently, several studies in
Taiwan have demonstrated a markedly increased incidence of
urinary tract transitional cell carcinoma (TCC) in RTx recipients,
with an incidence rate of 4.1%.3,4 Primary TCC of the ovary is
a recently recognized subtype of epithelial cancer, with an inci-
dence of 1e2%.5,6 The common symptoms of this tumor include* Corresponding author. Dr. Sung-Lang Chen, Department of Urology,
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doi:10.1016/j.jcma.2011.03.009abdominal pain, abdominal swelling or distention and weight
loss. Herein, we present a case of post RTx TCC of the ovary
found by routine sonography. The patient underwent total
abdominal hysterectomy and bilateral salpingo-oophorectomy
followed by postoperative chemotherapy.
2. Case report
A 67-year-old postmenopausal woman presented with bilat-
eral native kidney hydronephrosis 5 years after cadaveric RTx.
Bilateral native nephrouretectomyandbladder cuff excisionwere
performed. The pathologic report was only atrophied kidney and
no malignancy was observed. The post-operative course was
uneventful. Unfortunately, routine follow-up abdominal sono-
gram 8 years after RTx disclosed a 4.6 cm cystic and hypoechoic
lesion over the left pelvis, possibly arising from the left ovary.
Physical examination did not show any pelvic palpable mass
because of ovoid abdomen of the patient. Computed tomography
disclosed a pelvic mass measuring 5.6  5.2  4.0 cm (Fig. 1).
There was no evidence of abnormal lymphadenopathy. The
liver and graft kidney were unremarkable. Routine blood andhinese Medical Association. All rights reserved.
Fig. 1. Abdominal computed tomography shows a complex adnexal mass
measuring 5.6  5.2  4.0 cm.
Fig. 2. Section showing transitional cell carcinoma (TCC) in a solid trabecular
growth pattern that closely resembles TCC of the bladder. Foci of glandular
differentiation are evident (arrow). (Hematoxylin & eosin, 100).
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investigation of tumor markers before surgery showed mildly
elevated serum CA125 (35 U/mL; normal, 0e30 U/mL), but
other markers including CA153, carcinoembryonic antigen and
CA199 were all within normal ranges.
The patient underwent surgery under the impression of
malignant ovarian tumor. The consistency of thewhite tumorwas
rubbery-firm, and it measured 6.5  5.5  4.0 cm in size. On
section, the mass was solid and ill-defined; a cyst measuring
4.3 2.9 1.2 cmwas identified within the compressed ovarian
tissue. The cystic surface was intact and smooth with no rupture.
After resection, there was approximately 150 mL of tan-colored
cystic fluid in the cystic content. Grossly, several mural nodules,
with the largest one about 0.6 cm,were noted on the inner surface
of the cyst. Parasurgical frozen-section biopsy of the mural
nodules demonstrated the presence of an ovarian malignancy.
There was no enlargement of the paraaortic lymph node on
palpation. Therefore, surgical staging procedures including total
abdominal hysterectomy, bilateral salpingo-oophorectomy and
pelvic lymph node dissection were performed. The ascites was
also sent for cytologic examination.
Microscopic examination of the ovarian tumor showed high-
grade TCC with direct invasion to the wall of the fallopian tube
(Fig. 2). Tumor cells resembled those occurring in the urinary tract,
and they lacked a benign or borderline Brenner tumor component.
Therewas nometastatic lesion, and the cytology of the ascites was
also negative for malignant cells. The final diagnosis was TCC of
the left ovary, high grade, stage IIA. Immunohistochemical studies
showed that most tumor cells were cytokeratin (CK) 14 positive
and CK20 negative (Fig. 3). Furthermore, CK 7 was positive only
for tumor cells with glandular differentiation.Mucin stainwas also
negative for tumor cells.After recovering from surgery, the patient received post-
operative chemotherapy with carboplatin (300 mg/m2) and
gemcitabine (1000 mg/m2) every 3 weeks for four cycles. The
CA125 level returned to normal range after the first course of
chemotherapy. The patient is being regularly followed up at
our outpatient department and has been disease-free for 8
months.3. Discussion
TCC of the ovary was first defined by Austin and Norris in
1987.7 They reported a group of patients who had ovarian
tumors presenting with histological features similar to those
seen in a malignant Brenner tumor, but the tumors lacked the
associated benign Brenner tumor component. In addition to
not having a benign Brenner tumor component, TCC lacks the
prominent stromal calcification. Because TCC of the ovary has
close morphological similarities to TCC of the bladder and it
behaves more aggressively than malignant Brenner tumor,
Austin and Norris concluded that ovarian TCC arises directly
from the pluripotential surface epithelium of the ovary and
from cells with urothelial potential, rather than from a benign
or proliferative Brenner tumor precursor.7
Primary TCC is one of the subtypes of epithelial ovarian
cancer, with an incidence of 1e2%.5,6 Thus, when TCC of the
ovary is encountered, themain differential diagnoses are primary
ovarian TCC, metastasis from the urinary tract and malignant
Brenner tumor. The site of origin can be decided by the pattern of
distribution of the disease and the immunohistochemical stain-
ing. CK7 is expressed in ductal epithelium and transitional cells,
and CK20 is expressed in crypt cells and transitional cells.8 TCC
of the urinary tract is virtually always CK7þ/CK20þ.9,10
Ovarian TCCs are negative for CK20, thrombomodulin and
uroplakin III.11,12 Based on these findings, the combination of
CK7 and CK20 staining showed a very specific pattern for TCC
of the bladder and ovary.13 Our patient had undergone bilateral
native nephrouretectomy and bladder cuff excision for bilateral
Fig. 3. Immunohistochemical staining for: (A) CK7 is focally positive in
glandular differentiated areas (200) and (B) CK20 is negative for tumor cells
(200).
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kidney and no malignancy. The graft kidney was also unre-
markable on computed tomography. Routine cystoscopy
revealed no abnormality. The left resected ovary also disclosed
CK7positive andCK20negative immunohistochemical staining.
Therefore, the diagnosis was primary TCC of the left ovary.
Austin and Norris reported surgery alone for 14 patients
with stage S stage II. None of the patients presented free of
disease within 5 years.7 TCC of the ovary is reported to be as
sensitive to cisplatin-based chemotherapy as urinary tract TCC
and has a better prognosis than other types of common
epithelial tumors of the ovary. Gershenson et al. concluded that
advanced-stage ovarian TCC was significantly more chemo-
sensitive and associated with better prognosis than poorly
differentiated serous carcinoma.14 Kommoss et al. also docu-
mented that patients with ovarian TCC had better prognoses
compared to patients with all other types of ovarian carcinomas
after standard chemotherapy.15 An interesting characteristic of
cancers among renal transplant recipients is their aggressive-
ness, which is increased as compared with the remainder of thepopulation that has not received transplantation. The role of
immunosuppressive drugs as related to this aggressiveness
should be taken into account. Therefore, the lowest possible
dose of immunosuppressive agents in RTx recipients with
developing cancers is recommended.
RTx recipients in Taiwan are at extremely high risk for
TCC of the urinary tract. The development of TCC in RTx
recipients is likely multifactorial and cumulative.3 It is diffi-
cult to understand a cause/effect relationship between kidney
transplantation and the development of TCC. Whether or not
the development process of ovarian TCC has the same path-
ophysiological mechanism of urinary tract TCC after RTx
warrants further research.
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